The Deletion of Exon 3 in the Cardiac Ryanodine Receptor Is Rescued by β Strand Switching  by Lobo, Paolo A. et al.
Structure
ArticleThe Deletion of Exon 3 in the Cardiac Ryanodine
Receptor Is Rescued by b Strand Switching
Paolo A. Lobo,1 Lynn Kimlicka,1 Ching-Chieh Tung,1 and Filip Van Petegem1,*
1Department of Biochemistry and Molecular Biology, University of British Columbia, 2350 Health Sciences Mall, room 2.320, Vancouver,
BC V6T 1Z3, Canada
*Correspondence: filip.vanpetegem@gmail.com
DOI 10.1016/j.str.2011.03.016SUMMARY
Mutations in the cardiac Ryanodine Receptor (RYR2)
are linked to triggered arrhythmias. Removal of exon
3 results in a severe form of catecholaminergic poly-
morphic ventricular tachycardia (CPVT). This exon
encodes secondary structure elements that are
crucial for folding of the N-terminal domain (NTD),
raising the question of why the deletion is neither
lethal nor confers a loss of function. We determined
the 2.3 A˚ crystal structure of the NTD lacking exon
3. The removal causes a structural rescue whereby
a flexible loop inserts itself into the b trefoil domain
and increases thermal stability. The exon 3 deletion
is not tolerated in the corresponding RYR1 domain.
The rescue shows a novel mechanism by which
RYR2 channels can adjust their Ca2+ release proper-
ties through altering the structure of the NTD. Despite
the rescue, the deletion affects interfaces with other
RYR2 domains. We propose that relative movement
of the NTD is allosterically coupled to the pore region.INTRODUCTION
Excitation-contraction (E-C) coupling in cardiac and skeletal
muscle requires the rapid release of Ca2+ from the sarcoplasmic
reticulum (SR) into the cytoplasm. This release is mediated by
ryanodine receptors (RyRs), 2.2 MDa channels located in the
SR membrane. Three different mammalian isoforms have been
isolated to date (RYR1-3). Whereas RYR1 predominates in skel-
etal muscle, RYR2 is the major type found in cardiac myocytes
(Giannini et al., 1995). RyR3 ismore ubiquitous andwas originally
found in rabbit brain (Hakamata et al., 1992). Electron micros-
copy studies have shown that the bulk of the RyR structure is
located in the cytoplasm, with only 10% forming the transmem-
brane region (Liu et al., 2001; Ludtke et al., 2005; Samso et al.,
2005, 2009; Sharma et al., 1998; Wang et al., 2007). Opening
and closing of the channel is linked to long-range allosteric
motions within the cytoplasmic ‘‘foot’’ (Samso et al., 2009). It
forms docking sites for many auxiliary proteins that affect the
gating properties of the channel (Bers, 2004; Lehnart et al.,
2005; Marx et al., 2000; Zalk et al., 2007). A number of high-
resolution studies have described the structures of individual
RyR domains, including the N-terminal domains (Amador et al.,790 Structure 19, 790–798, June 8, 2011 ª2011 Elsevier Ltd All rights2009; Lobo and Van Petegem, 2009; Tung et al., 2010) and
a binding site for the Ca2+ binding proteins calmodulin (Maxim-
ciuc et al., 2006) and S100A1 (Wright et al., 2008).
RYR1 and RYR2 are targets for an increasing list of disease
mutations. Individual amino acid substitutions in RYR1 can
result in malignant hyperthermia (MH) and central core disease
(CCD)(Cabello and Ricoy-Campo, 2003; MacLennan and Phil-
lips, 1992; Robinson et al., 2006; Shepherd et al., 2004). Substi-
tutions in RYR2 have been found to underlie catecholaminergic
polymorphic ventricular tachycardia (CPVT) and arrhythmo-
genic right ventricular dysplasia type 2 (ARVD2), conditions trig-
gered in response to physical or emotional stress, resulting in
cardiac arrhythmias and sometimes sudden cardiac death
(George et al., 2007; Laitinen et al., 2001; Priori et al., 2001;
Thomas et al., 2007). RyRs are activated by Ca2+ and most
disease mutations characterized to date confer a gain of func-
tion to the channels: they have a lowered threshold for either
cytoplasmic Ca2+ (calcium induced calcium release [CICR]) or
SR Ca2+ levels (store overload induced calcium release
[SOICR]) and are more sensitive to activating agents (George
et al., 2003; Jiang et al., 2002, 2004, 2005, 2008; Koop et al.,
2008; MacLennan and Chen, 2009). In the case of cardiac
RyRs, the increase in cytosolic Ca2+ leads to an increased
activity of the Na+/Ca2+ exchanger, resulting in delayed after
depolarizations (DADs) (Fozzard, 1992; Lehnart et al., 2008;
Marban et al., 1986).
A large number of mutations cluster in the N-terminal 600
residues of RYR2 (Medeiros-Domingo et al., 2009). A very severe
form of CPVT is caused by removal of the entire third exon in
RYR2 (Bhuiyan et al., 2007; Marjamaa et al., 2009; Medeiros-
Domingo et al., 2009). In addition to the typical CPVT-related
symptoms, patients with the RYR2 exon 3 deletion develop atrio-
ventricular block, sinoatrial node dysfunction, atrial fibrillation,
and atrial standstill (Bhuiyan et al., 2007).
The RYR2 exon 3 is situated in the N-terminal domain (resi-
dues 1–217, referred to as ‘‘RYR2A’’ throughout this text). A
recent crystal structure of this domain shows a fold consisting
of 12 b strands forming a b trefoil core (Lobo and Van Petegem,
2009). In addition, a 310 helix and a helix are found before and
after strand b4, respectively. An almost identical fold is found in
RYR1 (Amador et al., 2009; Lobo and Van Petegem, 2009;
Tung et al., 2010). Exon 3 forms a crucial part of the structure,
consisting of 35 amino acids that build up a loop region, the
310 helix, b4, and the a helix. Being intimately entangled with
the remainder of the domain, removal of just the b strand would
already be predicted to cause misfolding of RYR2A, something
that would likely affect folding ofmultiple RyR domains and resultreserved
Figure 1. Overall Structure
(A) Cartoon representation of wild-type RyR2A.
Exon 3 is shown in green, and the flexible loop,
replacing exon 3 in the RYR2A Dexon3 structure,
is indicated by a red dotted line.
(B) Cartoon representation of RYR2A Dexon3,
shown in the same orientation. The rescue
segment is shown in red. Electron density for the
rescue segment in shown in Figure S1.
(C) Superposition of RYR2A and RYR2A Dexon3.
Structure
Structural Rescue in RYR2 Dexon3in an overall loss-of-function phenotype. Although severe, the
exon 3 deletion is not strictly lethal, and its CPVT symptoms
suggest mechanisms similar to individual RYR2 point mutations
conferring a gain of function. How is such a drastic deletion toler-
ated in the ryanodine receptor, and why does it not cause loss of
function?We previously found that RYR2ADexon3 is still soluble
and does not aggregate (Lobo and Van Petegem, 2009). Here,
we reinvestigate the folding properties and show a 2.3 A˚ crystal
structure of RYR2A Dexon3 (residues 1–217). The structure
shows a drastic rearrangement that rescues the N-terminal
domain. These motions underline an unusual structural plasticity
of the RYR2 N-terminal region, and show that RyRs have
adopted an extra strategy to fine-tune their functional properties.
RESULTS
Crystal Structure of the RYR2 Dexon3 N-Terminal
Domain
The exon 3 deletion in RYR2 abolishes residues 57 to 91 in the
N-terminal domain (RYR2A). It removes a b strand (b4) that is
part of a b trefoil core, and an a helix (Figure 1A). The deletion
did not seem to cause unfolding or aggregation of the domain,
but even seemed to increase the melting temperature (Lobo
and Van Petegem, 2009). How is it possible that removal of
a b strand from a b sheet enhances the thermal stability?
In order to investigate this paradox, we solved the crystal
structure of the RYR2A Dexon3 domain at 2.3 A˚. In par with
the improved thermal stability, the protein was easier to crystal-
lize than wild-type, resulting in over 50 initial crystallization hitsStructure 19, 790–798, June 8, 2011in a random screen of 7x96 conditions,
compared with only two hits for wild-
type RYR2A.
We initially used phases from a model
consisting of the RYR2A wild-type struc-
ture, missing all exon 3 residues. The
RYR2A Dexon3 crystals contain two
molecules in the asymmetric unit. All
further comparisons, unless noted other-
wise, are performed with chain B.
Surprisingly, difference electron density
was clearly present in the region previ-
ously encoded by exon 3. Although no
density was visible for the a helix, another
element compensated for the loss of both
b4 and the 310 helix. The density was of
sufficient quality to assign the right
sequence to this region, and the identityof two methionines in the segment was confirmed by anomalous
data collected on selenomethionine-substituted protein crystals
(see Figure S1 available online). The complete structure of
RYR2A Dexon3 is shown in Figure 1B. The protein is folded as
a b trefoil, but evidently misses the a helix. Instead of forming
a collapsed structure, the main chain atoms seem to superpose
very well with the ones in wild-type RYR2A (Figure 1C). Both
structures superpose with an rmsd of 0.901 A˚ for 136 Ca atoms
(based on superposition of chain A in both models).
Identity of the New b Strand
The resolutionof thestructure, togetherwith theanomaloussignal,
allowed an unambiguous assignment of the residues replacing
b4 and the 310 helix. These correspond to the sequence
93VDVEKWKFMMKT104,which ispart of a flexible loopconnecting
a1 tob5 inwild-typeRYR2A.BothRYR1AandRYR2Ahaveflexible
linkers connecting a1 and b5, but it is particularly longer in RYR2,
containing a 12 amino acid insertion that is unique to RYR2
(LoboandVanPetegem,2009).This representsanunprecedented
case of ‘‘rescue’’ of a drastic disease mutation: an otherwise flex-
ible loopbecomesab strand, and thuspreserves thedomaincore.
Comparison of the b4 Fit into the b Sheet
An alignment of the residues forming the fourth b strand in
RYR2A and RYR2A Dexon3 shows that the identities of the cor-
responding residues are completely dissimilar (Figures S2
and S3). How is it possible that two entirely different sequences
can fit into the same complementary surface? Figures 2A and 2B
compare the b4 region in RYR2A and RYR2A Dexon3. In bothª2011 Elsevier Ltd All rights reserved 791
Figure 2. Contacts with Exon 3 and the Rescue Segment
(A and B) Comparison of contacts between exon 3 and the remainder of wild-type RYR2A (A) and between the rescue segment and the rest of the RYR2ADexon3
domain (B). Exon 3 and the rescue segment are shown as sticks. The remainder is shown in surface representation, indicating hydrophobic (green), and positively
(blue) and negatively (red) charged side chains.
(C) Inner view of the deep pocket binding F67 (RYR2A) or W98 (RYR2A Dexon3). Side chains lining the pocket are shown in sticks.
(D) Inner view of the deep pocket binding L69 (RYR2A) or F100 (RYR2A Dexon3). A superposition of exon 3 and the rescue segment is shown in Figure S3.
Structure
Structural Rescue in RYR2 Dexon3cases, the strand binds to a predominantly hydrophobic surface.
The most extensive interactions are formed by two hydrophobic
residues binding in deep pockets. In RYR2A, one pocket is filled
by the side chain of F67, whereas the other is only partially filled
by L69. In RYR2A Dexon3, these are replaced byW98 and F100,
both of which provide more contacts with the hydrophobic resi-
dues in the pockets (Figures 2C and 2D). These extra contacts
show that the rescue segment adopts a better fit into the
remainder of the domain, likely causing the improved stability
of RYR2A Dexon3.
Additional Structural Plasticity
In addition to the large rearrangement, structural plasticity is
present in another b strand (b3). The conformation between792 Structure 19, 790–798, June 8, 2011 ª2011 Elsevier Ltd All rightsboth chains in the asymmetric unit differs: in chain A, the confor-
mation is very similar to the one observed in wild-type RYR2A,
but in chain B there is a one amino acid shift in the sequence:
a pocket normally filled up by L49 is now filled up by F48
(Figure 3A; Figure S4). The shift in register is accompanied by
a shift in the main chain away from the center of the protein.
This allows the bulkier phenylalanine side chain to fit in a pocket
otherwise filled up by the leucine residue. This structural rear-
rangement is allowed, in part, by flexible loops: both linkers con-
necting b3 to neighboring strands have missing electron density
and are thus interpreted to be flexible. Because b3 is part of
a b sheet, its shift is correlated with a translation of the neigh-
boring strand (b2), which further induces changes in the 310 helix
(Figure 3B). The rearrangement of b3 may be the direct result ofFigure 3. Mobility of Strands b2 and b3
(A) Superposition of b3 of RYR2A Dexon3 chain A
(dark blue) and chain B (light blue), indicating the
shift in amino acid register. The surface represents
the rest of the RYR2A Dexon3. An alternative view
is presented in Figure S4.
(B) Superposition of the main chains of b2, b3, and
the 310 helix of wild-type RYR2A (pink) and RYR2A
Dexon3 chain B. RYR2A Dexon3 chain A follows
the main chain of the wild-type RYR2A very well
and is not shown for clarity. Arrows indicate the
relative shifts of the main chains upon deletion of
exon 3.
reserved
Figure 4. Thermal Unfolding
Thermal melting curves for wild-type (WT) RYR2A (gray) and RYR2A Dexon3
(black) using CD at 217 nm. The data are normalized. Increasing temperature
leads to a more negative molar ellipticity.
Figure 5. Size Exclusion Chromatography
Gel filtration (Superdex 200) chromatograms for various N-terminal domain
constructs fused to MBP. The curve for RYR1A Dexon 3 has been scaled up
slightly for clarity. The arrow indicates the void volume. Inset: plot of molecular
weight (logarithmic scale) versus elution volume. Black dots indicatemolecular
weight standards, and the line corresponds to a linear fit of log(MW) versus
elution volume. Arrows indicate the four samples. Both RYR1A Dexon3 and
RYR2A Dexon3/W98A/F100A are mainly present near the void volume, indi-
cating large aggregation. Expected / observed molecular weights: RYR2A
Dexon3 (65.1/74.7 kDa), RYR2A Dexon3 WF-AA (64.9/2890 kDa),
RYR1A(67.2/78.9 kDa), RYR1A Dexon3 (63.6/2850 kDa).
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Structural Rescue in RYR2 Dexon3the exon 3 deletion, as this removes C65, a cysteine residue
involved in a labile disulfide bridge with C36 (Lobo and Van
Petegem,2009).TheC36sidechainnowpoints inadifferentdirec-
tion (Figure 3B). Because C36 is incapable of forming a disulfide
bridge with the deleted C65, restraints on the main chain of b2
are removed, which translates to increased mobility of the neigh-
boring strand b3. The overall structural plasticity in RYR2A likely
facilitates the incorporation of an entirely different segment into
the fold. The conformational changes are shown in Movie S1.
Thermal Melting Analysis of the RYR2 Dexon3 Mutation
Wepreviously found the RYR2ADexon3 variant to be still soluble
and to be thermally more stable thanwild-type RYR2A (Lobo and
Van Petegem, 2009). The used fluorophore (Sypro Orange)
reports on the hydrophobicity of the environment, and hence
the availability of hydrophobic residues as the protein unfolds.
In order to see whether this effect extends to secondary struc-
ture unfolding, and to increase the resolution of the unfolding
transitions, we revisited this phenomenon using circular
dichroism (CD). Figure 4 shows thermal melting curves using
the CD signal at 217 nm for RYR2A and RYR2A Dexon3. The
exon 3 deletion shows two distinct transitions, with midpoints
around 55C and 66C, which correspond well with the previ-
ously reported values using thermofluor (Lobo and Van Pete-
gem, 2009). Whereas earlier experiments had shown a single
transition for wild-type RYR2A, the CD melting uncovers
a smaller transition at higher temperature as well. The main
RYR2A transition has a midpoint near 52C, but the midpoint
of the smaller transition could not be obtained in a reliable
manner with either a Boltzmann fit or a first derivative plot. It
therefore seems that the wild-type RYR2A domain unfolds in
two steps, and that the exon 3 deletion causes a significant
stabilization of one of the individual folding units.
The Importance of RYR2 Residues W98 and F100
in Rescue of Dexon3
If the RYR2 a1-b5 loop is responsible for replacing exon 3, then
the removal of key residues in this segment should causeStructure 19misfolding of the protein. Because the structure suggests that
W98 and F100 seemed to make the most extensive interactions,
binding into deep hydrophobic pockets, we prepared the double
mutation W98A/F100A in the RYR2A Dexon3 background. The
protein was expressed as a fusion protein with maltose binding
protein (MBP) at its N terminus. An analytical gel filtration chro-
matogram shows that the fusion protein elutes in the void volume
of the column (Figure 5), indicating heavy aggregation likely due
to misfolding.
The rescue loop is unique to RYR2 (Lobo and Van Petegem,
2009). An extensive sequence comparison shows that it is only
present in RYR2 from mammals and birds, but not in any RyR
from other vertebrates or in invertebrates. In the sequences
that do contain the insert, the residues are highly conserved
(Figure 6).
Because RYR1 misses all of the residues that replace exon 3,
a deletion of exon 3 should not be tolerated in this isoform. We
prepared a Dexon3 variant of RYR1A (residues 1–205), and gel
filtration chromatography of the fusion protein also indicated
strong aggregation, likely due to misfolding (Figure 5). An exon
3 deletion in full-length RYR1 is therefore highly likely to have
a more drastic effect than in RYR2.The Exon 3 Deletion Affects Interfaces with Other RyR
Domains
Although the lost b strand is rescued, the RYR2 exon 3 deletion
still causes a very severe phenotype (Bhuiyan et al., 2007).
Despite conservation of the b trefoil core, the a helix is not
replaced, and the loop preceding the 310 helix is shortened by
4 residues. In addition, the identities of residues in the rescue, 790–798, June 8, 2011 ª2011 Elsevier Ltd All rights reserved 793
Figure 6. Sequence Alignment of the Rescue Segment in RYR2 from
Various Species
The segment is only found in RYR2 from mammals and birds. With the
exception of one species (Taeniopygia guttata), all residues are highly
conserved. A sequence alignment of wild-type andmutant segments in shown
in Figure S2.
Structure
Structural Rescue in RYR2 Dexon3segment are completely different from the corresponding exon 3
residues.
A crystal structure of the first three domains of RYR1 was
recently solved (Tung et al., 2010). The three domains (A,B,C)
interact with each other and because of the high sequence
conservation in this region, the overall structure and domain-
domain interfaces are likely similar in RYR2. We therefore super-
posed the RYR2A domain onto the RYR1ABC structure (Fig-
ure 7A). Residues belonging to exon 3, in particular the 310 helix
and preceding loop, are involved in contacts with both domain B
and C. The a helix is involved in an interface with electron dense
columns extending toward the transmembrane segment
(Figures 7B and 7C; Movie S2). Deletion of the helix would there-
fore completely disrupt this interface, thus being responsible for
a very severe disease phenotype.DISCUSSION
Distinct mutations in RYR2 are known to result in CPVT. Accord-
ing to the current model, the combined effect of catecholamines
and disease mutations causes premature or prolonged leak of
Ca2+ into the cytoplasm, inadvertently activating the Na+/Ca2+
exchanger. The latter is responsible for the efflux of one Ca2+
ion in return for the influx of three Na+ ions, an electrogenic
event that can result in delayed after depolarizations (Fozzard,
1992; Marban et al., 1986). A number of CPVT causing
mutations in RYR2 have been studied at themolecular level, con-
firming a gain of function that is compatible with unsolicited Ca2+
leak (George et al., 2003; Jiang et al., 2002, 2004, 2005; Koop
et al., 2008; MacLennan and Chen, 2009). Loss-of-function
mutations cause a very different phenotype, known as catechol-
aminergic idiopathic ventricular fibrillation (Jiang et al., 2007).
Almost all known RYR2 disease mutations are single amino
acid substitutions, primarily focused in three ‘‘hot spots’’ located
in the N-terminal region, a central domain, and the presumed
transmembrane region. Some mutations have been found
outside of these regions, and the apparent presence of hot spots
could be due to a sequencing bias (Betzenhauser and Marks,794 Structure 19, 790–798, June 8, 2011 ª2011 Elsevier Ltd All rights2010; Robinson et al., 2006). A very severe form of CPVT is
caused not by a simple amino acid substitution, but by the dele-
tion of the entire third exon in the N-terminal domain of RYR2.
Because this 35 amino acid exon forms an integral part of the
domain, it is surprising that its deletion does not cause general
misfolding and aggregation, an effect that would preclude
a gain of function typically associated with CPVT.
We solved a crystal structure of the Dexon3 variant of the
RYR2 N-terminal domain at 2.3 A˚ resolution. An unusual rear-
rangement is responsible for the structural rescue of the domain:
a 12 amino acid stretch in a flexible loop salvages the b trefoil
core by substituting both a 310 helix and b strand lost by the dele-
tion. The contacts with the rescue segment are more extensive
than with the original b strand, explaining the improved thermal
stability of the protein. The rescue is accompanied by shifts in
the main chain of two other b strands, one of which undergoes
a 1 residue translation in the sequence register. The latter shifts
are not strictly required, as they are only observed in one of the
two molecules in the asymmetric unit. Overall, these conforma-
tional changes highlight the unusual structural plasticity of the
RYR2 N-terminal domain.
The exon 3 residues are involved in two interfaces, including
interactions with the neighboring domain B, and with electron
dense columns that connect the N-terminal domain with the
transmembrane region. Single point mutations in both regions
have already been shown to cause disease. In particular, muta-
tions in strand b4 and the preceding 310 helix are known to cause
CPVT in RYR2 (L62F) (Medeiros-Domingo et al., 2009) and
malignant hyperthermia in RYR1 (D60N, S71Y). These underline
the importance of this domain-domain interaction, and a replace-
ment of the interface with a completely dissimilar sequence is
therefore likely to destabilize this interaction drastically. In addi-
tion, the deleted a helix seems to play a prime role in normal RyR
function, as individual point mutations on a1 (A77V, M81L) are
known to cause CPVT (d’Amati et al., 2005; Medeiros-Domingo
et al., 2009). The A77V mutation is known to cause only local
changes to the RYR2A surface, suggesting this forms an impor-
tant interaction site with neighboring RYR2 domains (Lobo and
Van Petegem, 2009). The recent crystal structure of the
N-terminal hot spot has allowed an unambiguous placement of
this segment into the available cryo-EM maps of RYR1 (Tung
et al., 2010). The hot spot is located in the cytoplasmic area,
forming a continuous 240 kDa ring around the 4-fold axis.
Cryo-EM studies comparing RYR1 in the open and closed
state have shown that the N-terminal hot spot is involved in
extensive conformational changes (Samso et al., 2009; Tung
et al., 2010). Based on these observations, we postulate the
following working hypothesis. Normal gating of the channel
includes an allosteric coupling between the transmembrane
region and the N-terminal hot spot. The latter acts as a brake
on channel opening. Domain A forms a link through an interface
involving the a-helical segment and electron dense columns
reaching toward the transmembrane segment (Figures 7B–7D).
In addition, other links may exist through coupling of domain A
with domains B, C, and other RyR domains. Movement in the
pore region therefore necessitates a relative motion of domain
A, a process that requires free energy through the disruption of
several weak interactions. This energy is normally obtained
from bound ligands and proteins in a regulated fashion.reserved
Figure 7. The Exon 3 Deletion Affects Two Interfaces within Full-Length RYR2
(A) Hybrid model consisting of RYR2A exon 3 (green) or the rescue segment (red) and RYR1BC (gray surface) derived from the RYR1ABC structure. Although
details within the A-B interface likely differ between RYR1 and RYR2, the high sequence similarity suggests that exon 3 is also involved in contacts with domain B
in RYR2.
(B and C) Position of RYR2A and exon 3 within the RyR cryo-EMmap. Only one monomer is shown for clarity. The helix is part of an interface with a RyR domain
that extends toward the transmembrane region.
(D) Model for the effect of the exon 3 deletion on channel gating. Movement within the transmembrane region is allosterically coupled to the N-terminal domains,
involving motions of RYR2A relative to neighboring domains. Disruption of two interfaces reduces the energetic cost to move RYR2A, resulting in facilitated pore
opening.
Structure
Structural Rescue in RYR2 Dexon3Weakening the contacts of domain A with at least three neigh-
boring domains thus allows for conformational changes with
a lower energetic penalty. This then allows for facilitated opening
of the pore, resulting in inadvertent Ca2+ release under condi-
tions that are normally insufficient to open the pore. The disease
phenotype is only revealed upon adrenergic stimulation,
involving a role for PKA. The PKA phosphorylation site is not in
the N-terminal region, and is likely at the outer surface of the
RyR (Jones et al., 2008). It therefore seems that the transmem-
brane region is under the control of multiple allosteric sites,
and that the combined effect of disturbing multiple brakes
(e.g., through disease mutation and PKA phosphorylation) leads
to channel opening.
The natural question arises about the identity of the regions
contacting domain A. Several groups have suggested that the
N-terminal hot spot may interact directly with the central disease
hot spot (Ikemoto and Yamamoto, 2002; Liu et al., 2010; Tateishi
et al., 2009). Based on the distribution of mutations in the
N-terminal hot spot however, it is likely that the second hot
spot cannot cover all observed interfaces between the domains
ABC and other RyR domains (Tung et al., 2010). The identity of
the electron dense columns therefore remains to be found. In
addition, since the RYR2A a helix is also involved in a lateral
interface (Tung et al., 2010), it cannot be excluded that coupling
to the pore occurs through other contact regions as well.
The rescue segment is unique to the RYR2 isoform. We there-
fore predict that a similar mutation in the skeletal muscle isoform,
RYR1, may have more drastic consequences for the overallStructure 19RYR1 structure. In agreement with this, the Dexon3 variant of
the RYR1 N-terminal domain heavily aggregates. Comparing
the RYR2 sequences of various species reveals that the rescue
segment only evolved late, as it is only observed in RyRs from
birds and mammals. Within these groups, the segment is highly
conserved, suggesting a functional role.
The number of possible sequenceswith a 12 amino acid stretch
is 4 3 1015. Even with some degree of structural plasticity, it is
implausible that the RYR2 a1-b5 loop is able to insert itself in
a b sheet by mere chance. Instead, evolutionary pressure seems
to have evolved a unique segment that can specifically form part
of the b trefoil domain. Two different scenarios could be consid-
ered. In the first, the two segments are in direct competition for
the same site in the b trefoil core. Because the rescue segment
appears to have a higher thermal stability, one could argue for
this segment to be favored. However, the N-terminal end of the
rescue segment immediately follows the a helix in wild-type
RYR2A, placing it 37 A˚ away from its observed position in
RYR2A Dexon3. In order for this stretch to be part of the b sheet
in wild-type RYR2, the a helix cannot be at its observed location
in the wild-type RYR2A structure, which would add an energetic
penalty. Given the constant position of the helix in all solved wild-
type and mutant structures of the first domain (Amador et al.,
2009; Lobo and Van Petegem, 2009; Tung et al., 2010), the rescue
segment is only likely to compete if another domain or protein is in-
teracting with the helix. Four different structures are available for
‘‘full-length’’ RYR2A: two point mutants (A77V, V186M), and two
molecules in the asymmetric unit of the wild-type crystal structure, 790–798, June 8, 2011 ª2011 Elsevier Ltd All rights reserved 795





a, b, c (A˚) 95.370, 44.204, 76.606
a,b,g () 90.00 90.98 90.00
Resolution (A˚) 50.00–2.30 (2.38-2.30)a
Rsym or Rmerge 0.065 (0.200)
I / s(I) 10.8 (2.4)













Bond lengths (A˚) 0.012
Bond angles () 1.435
Ramachandran (core/allowed %) 89.6/10.4
a Values in parentheses are for highest resolution shell.
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Structural Rescue in RYR2 Dexon3(Lobo and Van Petegem, 2009). In all cases, the rescue segment is
part of a flexible loop, confirming that this is the most favored
conformation in the absence of additional stabilizing elements.
However, this is only a property intrinsic to the isolated domain
A, and in the context of the full-length channel, the melting
temperature and preferred conformation may differ.
A second, more attractive, scenario is alternative splicing,
whereby a splice variant missing exon 3 has a tissue-specific
role. Due to the clear disease phenotype it is unlikely that such
a splice variant would be widely expressed in the heart. Many
other tissues however are known to express RYR2, including
various parts of the central nervous system (Ledbetter et al.,
1994). The main effect of such alternative splicing would be to
remove the a-helical segment, representing an interesting setup:
rather than removing the a helix individually, the splicing would
remove several segments and then replace everything but the
helix. Although a Dexon3 splice variant has not yet been identi-
fied in nondiseased individuals, RYR2 messenger transcripts in
pancreatic islets, cerebrum, and cerebellum have been found
to miss an important part of the rescue segment, deleting 7 resi-
dues that includeW98 (Takasawa et al., 2010). These RYR2 vari-
ants have no significant difference in ryanodine binding or
expression levels, suggesting that the rescue segment only
has a functional role when exon 3 has been removed.
Because Ca2+ is a very potent intracellular secondmessenger,
fine-tuning the total amount and time of its entry into the cyto-
plasm is of prime importance. The structure of the RYR2A
Dexon3 domain suggests that the ryanodine receptor has
evolved an additional means to regulate Ca2+ release, by altering
the shape of an individual domain. Future work will shed light on
the precise functional role of the rescue segment in wild-type
channels, and on the mechanistic steps that lead to increased
channel opening upon deletion of the RYR2 third exon.EXPERIMENTAL PROCEDURES
Cloning, Expression, and Purification
A full-length ryr2 Dexon3 cDNA clone was obtained from the lab of Wayne
Chen (University of Calgary). The corresponding N-terminal domain (residues
1–217) was cloned into the pET28HMT vector as described before (Lobo and
Van Petegem, 2009). The fusion protein was expressed in Escherichia coli
Rosetta (DE3) pLacI and selenomethionine labeling was performed using the
adjusted autoinduction media (Studier, 2005). Point mutations were generated
using the quikchange protocol (Stratagene). The rabbit RYR1 Dexon3
N-terminal domain (residue 1–205) was obtained by separate PCR of two frag-
ments (residues 1–56 and 92–205) which were ligated using a flanking BamHI
site and cloned into pET28HMT.
The purification of RYR2A Dexon3 was performed as for WT RYR2A (Lobo
and Van Petegem, 2009). For the RYR1A Dexon3 and RYR2A Dexon3/
W98A/F100A proteins, cell lysate was loaded on a PorosMC column (Tosoh
Biosep), and eluted with buffer A (250 mM KCl + 10 mM HEPES [pH 7.4]) +
300 mM imidazole. The elution was dialyzed against buffer A, applied to an
amylose column (New England Biolabs) and eluted with buffer A + 10 mM
maltose. Five hundred microliter of the elution was applied to an analytical
Superdex200 column (GE Healthcare) in buffer A.
Circular Dichroism
RYR2A and RYR2A DExon3 were dialyzed against 10 mM Na3PO4 (pH 7.4),
50 mM KCl, and 2 mM b-mercaptoethanol. Concentrations were determined
using the calculated extinction coefficient at 280 nm in the presence of 6 M
Guanidine (Edelhoch, 1967). Thermal melts were performed using a Jasco
J810 CD spectropolarimeter on samples at a concentration of 5 mM. Prior to796 Structure 19, 790–798, June 8, 2011 ª2011 Elsevier Ltd All rightsthe temperature scan, CD spectra of the samples and dialysis buffer alone
were collected over a spectral window of 190–300 nm at 25C. Thewavelength
was then fixed at 217 nm while the temperature was increased from 7C to
83C at a rate of 1C/min. Themidpoints of the transitions in themelting curves
were obtained by taking the maximum values of the slopes.
Crystallization and Data Collection
Crystals were obtained by hanging drop vapor diffusion at 10%–15% PEG
1000. They were transferred to the same condition supplemented with 25%
2-methyl-2,4-pentanediol and flash-cooled in liquid nitrogen. Data sets were
obtained at the Stanford Synchrotron Radiation Lightsource (SSRL) beamline
11-1 and the Canadian Light Source (CLS) beamline 08ID-1, and processed
using the HKL2000 package (HKL Research). The best data used to solve
and refine the structure were collected at 0.9729 A˚.
Structure Solution and Refinement
A model consisting of the structure of wild-type RYR2A (PDB 3IM5) without
residues 57–91 was used for molecular replacement by Phaser (McCoy
et al., 2007). An anomalous difference map was created to confirm the posi-
tions of methionines in the rescue segment. Successive rounds of manual
modeling in COOT (Emsley and Cowtan, 2004) and refinement using
REFMAC5 (Murshudov et al., 1997), with TLS restraints applied to the indi-
vidual molecules of the asymmetric unit, led to the final structure. A composite
omit mapwas calculated with Phenix (Adams et al., 2010) to verify the absence
of residual model bias. Refinement statistics are available in Table 1.ACCESSION NUMBERS
Coordinates and structure factors for the RYR2A Dexon3 structures have been
deposited in the Protein Data Bank with accession code 3QR5.reserved
Structure
Structural Rescue in RYR2 Dexon3SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and two movies and can be
found with this article online at doi:10.1016/j.str.2011.03.016.
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